Inclusion across leading analyses reflects growing adoption of digital biomarkers and growing need for more rigorous measurement strategies in clinical development
New York, NY — March 17, 2026 — Koneksa, a measurement-science partner for clinical development, today announced its inclusion in multiple recent independent market reports examining the rapidly expanding digital biomarkers landscape.
Recent analyses from organizations including MarketsandMarkets, DelveInsight, and DataM Intelligence highlight strong projected growth for the global digital biomarkers market, driven by increasing prevalence of chronic diseases, growing adoption of wearable and sensor-based technologies, and rising demand for remote patient monitoring. As the field evolves from early exploration toward broader implementation, attention is shifting to a more fundamental challenge: whether digital measures can reliably detect meaningful treatment effects in real-world clinical settings.
This has direct implications for biopharmaceutical companies, including development timelines, trial success rates, and the ability to make confident decisions earlier. More sensitive and well-designed measurement approaches can accelerate the identification of effective therapies, improving development efficiency and expanding patient access to new treatments. As a result, greater emphasis is being placed not just on collecting digital data, but on how those measures are defined, integrated, and interpreted within clinical trials.
In response, organizations across the industry are increasingly seeking partners who can support this shift, developing validated, regulatory-aligned digital biomarker approaches while advancing integrated measurement design, multi-modal data collection, and longitudinal analysis. Koneksa supports this work across multiple therapeutic areas, including neuroscience, oncology, cardiovascular disease, and rare diseases, with experience extending into additional indications. Through collaborations with organizations such as The Michael J. Fox Foundation and Verily, Koneksa has contributed to advancing the use of digital measures in clinical research.
Koneksa’s inclusion in multiple independent market reports reflects the broader momentum seen across the digital biomarkers ecosystem. As the industry continues to mature, the focus is increasingly centered on generating reliable, high-quality evidence from digital endpoints. This begins with how measurements are designed, grounded in disease biology and aligned to the clinical question, so they can meaningfully detect change and support confident decision-making—an area in which Koneksa is playing a leading role.
Industry forecasts point to sustained expansion of the digital biomarkers sector over the coming decade, fueled by increased use of digital endpoints, the growth of decentralized and hybrid trials, and advances in sensor technologies and data analytics. As adoption increases, the ability to generate clear, interpretable, and decision-ready evidence will be critical to improving trial efficiency, reducing development risk, and accelerating the delivery of new therapies to patients.
About Koneksa Health
Koneksa is a measurement-science partner helping clinical development teams generate clearer, earlier, and more decision-ready evidence. By designing measurement strategies grounded in disease biology and therapeutic intent, Koneksa integrates physiological, clinical, and digital signals to reduce variability and clarify treatment effects. Through high-reliability execution and integrated scientific interpretation, Koneksa supports more confident decisions throughout the clinical development lifecycle.
Learn more at koneksahealth.com.